8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 6, 2026·SEC
Material company update
Mar 31, 2026·SEC
DiaMedica Therapeutics Inc.(DMAC)Earnings, Financials & Key Ratios
DMAC•NASDAQ
Price updated Jun 19, 2026
AboutDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Show more
- Revenue$0
- EBITDA-$34M-28.9%
- Net Income-$33M-34.0%
- EPS (Diluted)-0.70-16.7%
- ROE-67.68%-27.0%
DMAC Key Insights
DiaMedica Therapeutics Inc. (DMAC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 21.7% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 16.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DMAC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DMAC Price & Volume
DiaMedica Therapeutics Inc. (DMAC) stock price & volume — 10-year historical chart
Loading chart...
DMAC Growth Metrics
DiaMedica Therapeutics Inc. (DMAC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-30%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-10.94%
Return on Capital
10 Years-216.8%
5 Years-51.02%
3 Years-59.82%
Last Year-70.78%
DMAC Recent Earnings
DiaMedica Therapeutics Inc. (DMAC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.19-11.8%
$0.17
Rev
—
$14M
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.17+0.0%
$0.17
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.17-13.3%
$0.15
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.18+0.0%
$0.18
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.19vs $0.17-11.8% | —vs $14M |
| Q2 2026 | Mar 30, 2026 | $0.17vs $0.17+0.0% | — |
| Q4 2025 | Nov 12, 2025 | $0.17vs $0.15-13.3% | — |
| Q3 2025 | Aug 12, 2025 | $0.18vs $0.18+0.0% | — |
Based on last 12 quarters of dataView full earnings history →
DMAC Peer Comparison
DiaMedica Therapeutics Inc. (DMAC) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ATHA | 17.12M | 4.34 | -0.17 | -381.01% | 0.03 | |||
 ACMR | 7.28B | 109.87 | 80.20 | 15.24% | 9.48% | 5.13% | 0.16 | |
 NERV | 31.26M | 4.47 | -0.13 | |||||
 ANIK | 193.24M | 14.42 | -18.97 | -5.91% | -9.52% | -7.74% | 0.17 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 |
Compare DMAC vs Peers
DiaMedica Therapeutics Inc. (DMAC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DMAC Income Statement
DiaMedica Therapeutics Inc. (DMAC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 500K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | -100% | - | - | - | - | - | - | - |
Cost of Goods Sold | 4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -4K▲ 0% | 500K▲ 12600.0% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | 100% | - | - | - | - | - | - | - | - |
Gross Profit Growth % | -80.91% | 12600% | -100% | - | - | - | - | - | - | - |
Operating Expenses | 4.28M | 7.26M | 11.59M | 12.7M | 13.65M | 14M | 21.27M | 26.68M | 34.4M | 36.73M |
OpEx % of Revenue | - | 1452.2% | - | - | - | - | - | - | - | - |
Selling, General & Admin | 1.31M | 2.74M | 3.69M | 4.49M | 4.88M | 6.16M | 8.16M | 7.62M | 9.78M | 9.79M |
SG&A % of Revenue | - | 547.8% | - | - | - | - | - | - | - | - |
Research & Development | 3.21M | 4.52M | 7.9M | 8.21M | 8.77M | 7.84M | 13.11M | 19.06M | 24.61M | 26.95M |
R&D % of Revenue | - | 904.4% | - | - | - | - | - | - | - | - |
Other Operating Expenses | 6K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -4.52M▲ 0% | -6.76M▼ 49.6% | -11.59M▼ 71.5% | -12.7M▼ 9.5% | -13.65M▼ 7.5% | -14M▼ 2.6% | -21.27M▼ 51.9% | -26.68M▼ 25.5% | -34.4M▼ 28.9% | -36.73M▲ 0% |
Operating Margin % | - | -1352.2% | - | - | - | - | - | - | - | - |
Operating Income Growth % | -82.11% | -49.61% | -71.47% | -9.54% | -7.46% | -2.6% | -51.9% | -25.46% | -28.92% | - |
EBITDA | -4.51M | -6.75M | -11.57M | -12.68M | -13.62M | -13.98M | -21.24M | -26.64M | -34.35M | -36.69M |
EBITDA Margin % | - | -1349.2% | - | - | - | - | - | - | - | - |
EBITDA Growth % | -82.11% | -49.41% | -71.54% | -9.56% | -7.45% | -2.6% | -51.95% | -25.45% | -28.95% | -26.34% |
D&A (Non-Cash Add-back) | 4K | 15K | 21K | 21K | 24K | 25K | 30K | 39K | 43K | 43K |
EBIT | -4.26M | -5.55M | -11.59M | -12.7M | -13.65M | -14M | -21.27M | -26.68M | -34.4M | -36.73M |
Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.3M | 0 | 0 |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.3M | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 259K | 747K | 975K | 434K | 82K | 353K | 1.93M | 2.27M | 1.66M | 1.66M |
Pretax Income | -4.26M▲ 0% | -5.65M▼ 32.7% | -10.62M▼ 87.8% | -12.27M▼ 15.5% | -13.56M▼ 10.6% | -13.65M▼ 0.6% | -19.34M▼ 41.7% | -24.41M▼ 26.2% | -32.74M▼ 34.1% | -35.07M▲ 0% |
Pretax Margin % | - | -1130.8% | - | - | - | - | - | - | - | - |
Income Tax | -9K | 80K | 31K | 27K | 28K | 28K | 43K | 30K | 28K | 15K |
Effective Tax Rate % | 0.21% | -1.41% | -0.29% | -0.22% | -0.21% | -0.21% | -0.22% | -0.12% | -0.09% | -0.04% |
Net Income | -4.26M▲ 0% | -5.73M▼ 34.6% | -10.65M▼ 85.7% | -12.29M▼ 15.4% | -13.59M▼ 10.6% | -13.68M▼ 0.6% | -19.38M▼ 41.7% | -24.44M▼ 26.1% | -32.77M▼ 34.0% | -35.1M▲ 0% |
Net Margin % | - | -1146.8% | - | - | - | - | - | - | - | - |
Net Income Growth % | -91.62% | -34.6% | -85.72% | -15.43% | -10.58% | -0.62% | -41.72% | -26.12% | -34.05% | -30% |
Net Income (Continuing) | -4.26M | -5.73M | -10.65M | -12.29M | -13.59M | -13.68M | -19.38M | -24.44M | -32.77M | -35.09M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.72▲ 0% | -0.74▼ 2.8% | -0.89▼ 20.3% | -0.78▲ 12.4% | -0.65▲ 16.7% | -0.52▲ 20.0% | -0.60▼ 15.4% | -0.60▲ 0.0% | -0.70▼ 16.7% | -0.65▲ 0% |
EPS Growth % | -53.19% | -2.78% | -20.27% | 12.36% | 16.67% | 20% | -15.38% | 0% | -16.67% | -10.94% |
EPS (Basic) | -0.72 | -0.74 | -0.89 | -0.78 | -0.65 | -0.52 | -0.60 | -0.60 | -0.70 | - |
Diluted Shares Outstanding | 5.94M | 7.74M | 11.99M | 15.68M | 20.77M | 26.44M | 32.57M | 40.4M | 46.98M | 53.79M |
Basic Shares Outstanding | 5.94M | 7.74M | 11.99M | 15.68M | 20.77M | 26.44M | 32.57M | 40.4M | 46.98M | 53.79M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
DMAC Balance Sheet
DiaMedica Therapeutics Inc. (DMAC) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.49M | 17.97M | 8.84M | 27.92M | 45.44M | 33.84M | 53.67M | 44.61M | 60.63M | 52.36M |
Cash & Short-Term Investments | 1.35M | 16.82M | 7.88M | 27.51M | 45.11M | 33.5M | 52.9M | 44.15M | 59.89M | 51.33M |
Cash Only | 1.35M | 16.82M | 3.88M | 7.41M | 4.71M | 4.73M | 4.54M | 3.02M | 15.65M | 4.87M |
Short-Term Investments | 0 | 0 | 4M | 20.1M | 40.41M | 28.77M | 48.35M | 41.12M | 44.24M | 46.46M |
Accounts Receivable | 80K | 646K | 823K | 0 | 0 | 82K | 369K | 236K | 258K | 0 |
Days Sales Outstanding | - | 471.58 | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 47K | 350K | 243K | 0 | 0 | 227K | 481K | 1.03M |
Total Non-Current Assets | 308K | 367K | 217K | 174K | 112K | 560K | 485K | 1.74M | 742K | 717K |
Property, Plant & Equipment | 37K | 96K | 217K | 174K | 112K | 560K | 485K | 427K | 342K | 317K |
Fixed Asset Turnover | - | 5.21x | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 271K | 271K | 0 | 0 | 0 | 0 | 0 | 1.31M | 400K | 400K |
Total Assets | 1.8M▲ 0% | 18.34M▲ 917.7% | 9.05M▼ 50.6% | 28.09M▲ 210.3% | 45.55M▲ 62.1% | 34.4M▼ 24.5% | 54.16M▲ 57.5% | 46.34M▼ 14.4% | 61.37M▲ 32.4% | 53.08M▲ 0% |
Asset Turnover | - | 0.03x | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | -3.79% | 917.7% | -50.64% | 210.34% | 62.13% | -24.49% | 57.46% | -14.43% | 32.42% | 33.15% |
Total Current Liabilities | 1M | 1.3M | 1.32M | 2.03M | 1.52M | 2.17M | 2.79M | 5.39M | 5.13M | 5.75M |
Accounts Payable | 513K | 483K | 182K | 1.1M | 509K | 734K | 926K | 940K | 1.48M | 3.29M |
Days Payables Outstanding | 46.81K | - | - | - | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 60K | 0 | 0 | 0 | 0 | 0 | 0 | 115K |
Deferred Revenue (Current) | 0 | 34K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 439K | 417K | 657K | 0 | 0 | 667K | 766K | 4.35M | 3.54M | 2.34M |
Current Ratio | 1.49x | 13.87x | 6.70x | 13.77x | 29.82x | 15.61x | 19.27x | 8.28x | 11.81x | 9.11x |
Quick Ratio | 1.49x | 13.87x | 6.70x | 13.77x | 29.82x | 15.61x | 19.27x | 8.28x | 11.81x | 9.11x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 18K | 118K | 53K | 3K | 400K | 317K | 237K | 128K | 97K |
Long-Term Debt | 0 | 18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 97K |
Capital Lease Obligations | 0 | 18K | 118K | 53K | 3K | 400K | 317K | 237K | 128K | 469K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | -18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1M | 1.31M | 1.44M | 2.08M | 1.53M | 2.57M | 3.1M | 5.63M | 5.26M | 5.84M |
Total Debt | 0 | 23K | 178K | 118K | 52K | 469K | 400K | 340K | 240K | 212K |
Net Debt | -1.35M | -16.8M | -3.71M | -7.29M | -4.66M | -4.26M | -4.14M | -2.69M | -15.41M | -4.66M |
Debt / Equity | - | 0.00x | 0.02x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.13x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 799K▲ 0% | 17.02M▲ 2030.8% | 7.62M▼ 55.3% | 26.01M▲ 241.5% | 44.02M▲ 69.2% | 31.83M▼ 27.7% | 51.06M▲ 60.4% | 40.72M▼ 20.2% | 56.11M▲ 37.8% | 47.23M▲ 0% |
Equity Growth % | -35.87% | 2030.79% | -55.26% | 241.53% | 69.23% | -27.71% | 60.42% | -20.25% | 37.8% | 35.41% |
Book Value per Share | 0.13 | 2.20 | 0.64 | 1.66 | 2.12 | 1.20 | 1.57 | 1.01 | 1.19 | 0.88 |
Total Shareholders' Equity | 799K | 17.02M | 7.62M | 26.01M | 44.02M | 31.83M | 51.06M | 40.72M | 56.11M | 47.23M |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -40.23M | -45.97M | -56.62M | -68.91M | -82.5M | -96.18M | -115.56M | -140M | -172.77M | -182.81M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 610.88K | -24K | 2K | -2K | -51K | -74K | 6K | 23K | 50K | -26K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DMAC Cash Flow Statement
DiaMedica Therapeutics Inc. (DMAC) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -3.9M | -5.7M | -9.1M | -9.19M | -12.25M | -11.51M | -18.73M | -22.08M | -29.06M | -31.05M |
Operating CF Margin % | - | -1139.2% | - | - | - | - | - | - | - | - |
Operating CF Growth % | -29% | -46.05% | -59.8% | -0.91% | -33.39% | 6.05% | -62.7% | -17.88% | -31.65% | -163.62% |
Net Income | -4.26M | -5.73M | -10.65M | -12.29M | -13.59M | -13.68M | -19.38M | -24.44M | -32.77M | -35.1M |
Depreciation & Amortization | 4K | 15K | 21K | 21K | 24K | 25K | 30K | 39K | -899K | 52K |
Stock-Based Compensation | 409K | 620K | 1.16M | 1.84M | 1.56M | 1.5M | 1.68M | 2.08M | 3.85M | 1.96M |
Deferred Taxes | 84.6K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -93.6K | 39K | -25K | 48K | 219K | 53K | -1.15M | -1.27M | 82K | 966.11K |
Working Capital Changes | -44K | -636K | 387K | 1.2M | -461K | 585K | 93K | 1.51M | 675K | 1.07M |
Change in Receivables | -27K | -700K | -43K | 483K | 210K | 48K | -287K | 133K | -22K | -49.73K |
Change in Inventory | -756K | -372K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 248K | 372K | -301K | 917K | -590K | 225K | 192K | 14K | 535K | 1.8M |
Cash from Investing | -22K | -50K | -3.91M | -16.13M | -20.54M | 11.54M | -18.3M | 8.56M | -2.19M | -11.37M |
Capital Expenditures | -22K | -50K | -2K | -47K | -22K | -81K | -24K | -25K | -40K | -36.19K |
CapEx % of Revenue | - | 10% | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 13K | 16K | 2K | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 3.54M | 21.22M | 70K | 28.84M | 30.09M | -6K | 36.84M | 11.99M | 43.88M | 44.68M |
Debt Issued (Net) | 0 | 0 | -5K | -5K | -6K | -6K | -6K | -9K | -10K | -10.03K |
Equity Issued (Net) | 2.92M | 20.57M | 0 | 28.8M | 29.85M | 0 | 36.85M | 11.75M | 44.29M | 44.53M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 622K | 650K | 75K | 45K | 244K | 0 | 0 | 256K | -400K | 158.25K |
Net Change in Cash | -383K▲ 0% | 15.47M▲ 4139.2% | -12.94M▼ 183.6% | 3.53M▲ 127.2% | -2.7M▼ 176.6% | 21K▲ 100.8% | -185K▼ 981.0% | -1.52M▼ 720.5% | 12.62M▲ 931.5% | 2.28M▲ 0% |
Free Cash Flow | -3.92M▲ 0% | -5.75M▼ 46.5% | -9.1M▼ 58.4% | -9.23M▼ 1.4% | -12.27M▼ 33.0% | -11.59M▲ 5.6% | -18.75M▼ 61.8% | -22.1M▼ 17.9% | -29.1M▼ 31.7% | -31.09M▲ 0% |
FCF Margin % | - | -1149.2% | - | - | - | - | - | - | - | - |
FCF Growth % | -29.44% | -46.51% | -58.44% | -1.41% | -32.95% | 5.56% | -61.77% | -17.86% | -31.68% | -37.55% |
FCF per Share | -0.66 | -0.74 | -0.76 | -0.59 | -0.59 | -0.44 | -0.58 | -0.55 | -0.62 | -0.58 |
FCF Conversion (FCF/Net Income) | 0.92x | 0.99x | 0.85x | 0.75x | 0.90x | 0.84x | 0.97x | 0.90x | 0.89x | 0.89x |
Interest Paid | 0 | 11K | 2K | 2K | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 80K | 26K | 36K | 28K | 27K | 33K | 26K | 28K | 16K |
DMAC Key Ratios
DiaMedica Therapeutics Inc. (DMAC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -416.63% | -64.34% | -86.43% | -73.1% | -38.81% | -36.06% | -46.77% | -53.27% | -67.68% | -77.09% |
Return on Invested Capital (ROIC) | - | -2253.67% | -420.34% | -84.16% | -35.24% | -31.37% | -42.83% | -47.11% | -65.53% | -71.01% |
Gross Margin | - | 100% | - | - | - | - | - | - | - | - |
Net Margin | - | -1146.8% | - | - | - | - | - | - | - | - |
Debt / Equity | - | 0.00x | 0.02x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x |
FCF Conversion | 0.92x | 0.99x | 0.85x | 0.75x | 0.90x | 0.84x | 0.97x | 0.90x | 0.89x | 0.89x |
Revenue Growth | - | - | -100% | - | - | - | - | - | - | - |
Related:DMAC Dividend History·DMAC Revenue History·DMAC Price History·DMAC P/E History·DMAC Financial Ratios·DMAC Institutional Holders
DMAC SEC Filings & Documents
DiaMedica Therapeutics Inc. (DMAC) SEC filings — annual & quarterly reports (10-K, 10-Q)
DMAC Frequently Asked Questions
DiaMedica Therapeutics Inc. (DMAC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
DiaMedica Therapeutics Inc. (DMAC) grew revenue by 0.0% over the past year. Growth has been modest.
DiaMedica Therapeutics Inc. (DMAC) reported a net loss of $35.1M for fiscal year 2025.
Dividend & Returns
DiaMedica Therapeutics Inc. (DMAC) has a return on equity (ROE) of -67.7%. Negative ROE indicates the company is unprofitable.
DiaMedica Therapeutics Inc. (DMAC) had negative free cash flow of $31.1M in fiscal year 2025, likely due to heavy capital investments.